Literature DB >> 27553034

The Validity of the Comparative Interrupted Time Series Design for Evaluating the Effect of School-Level Interventions.

Robin Jacob1, Marie-Andree Somers2, Pei Zhu2, Howard Bloom2.   

Abstract

OBJECTIVE: In this article, we examine whether a well-executed comparative interrupted time series (CITS) design can produce valid inferences about the effectiveness of a school-level intervention. This article also explores the trade-off between bias reduction and precision loss across different methods of selecting comparison groups for the CITS design and assesses whether choosing matched comparison schools based only on preintervention test scores is sufficient to produce internally valid impact estimates. RESEARCH
DESIGN: We conduct a validation study of the CITS design based on the federal Reading First program as implemented in one state using results from a regression discontinuity design as a causal benchmark.
RESULTS: Our results contribute to the growing base of evidence regarding the validity of nonexperimental designs. We demonstrate that the CITS design can, in our example, produce internally valid estimates of program impacts when multiple years of preintervention outcome data (test scores in the present case) are available and when a set of reasonable criteria are used to select comparison organizations (schools in the present case).
© The Author(s) 2016.

Entities:  

Keywords:  comparative interrupted time series analysis; design replication; quasi-experimental methods; validation study; within-study comparison

Mesh:

Year:  2016        PMID: 27553034     DOI: 10.1177/0193841X16663414

Source DB:  PubMed          Journal:  Eval Rev        ISSN: 0193-841X


  7 in total

1.  Pediatric Outcomes After Regulatory Mandates for Sepsis Care.

Authors:  Kristin H Gigli; Billie S Davis; Jonathan G Yabes; Chung-Chou H Chang; Derek C Angus; Tina Batra Hershey; Jennifer R Marin; Grant R Martsolf; Jeremy M Kahn
Journal:  Pediatrics       Date:  2020-07       Impact factor: 7.124

2.  Effectiveness of antimalarial interventions in Nigeria: Evidence from facility-level longitudinal data.

Authors:  Nopphol Witvorapong; Kolo Yaro Yakubu
Journal:  Health Serv Res       Date:  2019-02-10       Impact factor: 3.402

3.  Association Between State-Mandated Protocolized Sepsis Care and In-hospital Mortality Among Adults With Sepsis.

Authors:  Jeremy M Kahn; Billie S Davis; Jonathan G Yabes; Chung-Chou H Chang; David H Chong; Tina Batra Hershey; Grant R Martsolf; Derek C Angus
Journal:  JAMA       Date:  2019-07-16       Impact factor: 56.272

4.  The comparative interrupted time series design for assessment of diagnostic impact: methodological considerations and an example using point-of-care C-reactive protein testing.

Authors:  Thomas R Fanshawe; Philip J Turner; Marjorie M Gillespie; Gail N Hayward
Journal:  Diagn Progn Res       Date:  2022-03-02

5.  The detection and prevention of adverse drug events in nursing home and home care patients: Study protocol of a quasi-experimental study.

Authors:  Benedikt Langenberger; Natalie Baier; Frank-Christian Hanke; Jacqueline Fahrentholz; Christina Gorny; Stephanie Sehlen; Katrin Christiane Reber; Sebastian Liersch; Ralf Radomski; Jens Haftenberger; Hans Jürgen Heppner; Reinhard Busse; Verena Vogt
Journal:  Nurs Open       Date:  2021-12-02

6.  Economic Analysis of Mandated Protocolized Sepsis Care in New York Hospitals.

Authors:  Donald S Bourne; Billie S Davis; Kristin H Gigli; Chung-Chou H Chang; Jonathan G Yabes; Grant R Martsolf; Jeremy M Kahn
Journal:  Crit Care Med       Date:  2020-10       Impact factor: 9.296

7.  Impact of the national home safety equipment scheme 'Safe At Home' on hospital admissions for unintentional injury in children under 5: a controlled interrupted time series analysis.

Authors:  Trevor Hill; Carol Coupland; Denise Kendrick; Matthew Jones; Ashley Akbari; Sarah Rodgers; Michael Craig Watson; Edward Tyrrell; Sheila Merrill; Elizabeth Orton
Journal:  J Epidemiol Community Health       Date:  2021-06-22       Impact factor: 3.710

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.